Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-237-7 | CAS number: 1314-60-9
Endpoint summary
Administrative data
Key value for chemical safety assessment
Additional information
Genetic toxicity testing was conducted with sodium hexahydroxoantimonate.
Based on the fact that diantimony pentoxide, sodium hexahydroxoantimonate and sodium antimonate contain antimony in the pentavalent oxidation state and that water solubility testing as well as transformation dissolution testing has shown similar dissolution pattern of pentavalent antimony cations form all three substances, read-across among the pentavalent antimony compounds (i.e. sodium hexahydroxoantimonate, sodium antimonate and diantimony pentoxide) is considered justified.
Short description of key information:
Sodium hexahydroxoantimonate did not induce an increase in mutation frequency in bacteria, micronuclei in cultured human lymphocytes and gene mutation in the tk locus of the L5178Y mouse lymphoma cell line. Therefore pentavalent antimony compounds such as sodium hexahydroxoantimonate, sodium antimonate and antimony pentoxide are considered as non-clastogenic and non-mutagenic.
Endpoint Conclusion: No adverse effect observed (negative)
Justification for classification or non-classification
The references Stone (2010) and Whitwell (2010) are considered as the key studies for in vitro mammalian genetic toxicity and the reference Spruth (2015) as the key study for bacterial reverse mutation. All key studies will be used for classification purposes. The overall results are as follows:
Sodium hexahydroxoantimonate did not show an increase in the mutation frequency in the bacterial reverse mutation assay when tested up to the maximum concentration of 5000 µg/plate following the pre-incubation an plate incorporation protocol in the presence and absence of metabolic activation.
Sodium hexahydroxoantimonate did not show a significant or dose-dependent increase in micronuclei in cultured human lymphocytes up to the maximum dose of 540 µg/mL.
Sodium hexahydroxoantimonate did not show a significant or dose-dependent increase in mutations in cultured mouse lymphoma cells (L5178Y) up to the maximum dose of 570 µg/mL.
The classification criteria according to regulation (EC) 1272/2008 as germ cell mutagen are also not met.
Further testing of in vivo genetic toxicity tests for
pentavalent antimony compounds such as sodium hexahydroxoantimonate, sodium antimonate and antimony pentoxide
is not considered necessary.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
